Kintor Pharma Announces Completion of Subject Enrollment in China Phase II Clinical Trial of Furitax for the Treatment of Female Hair Loss

SUZHOU, March 7, 2022 /PRNewswire/ -- On March 6, 2022, Beijing time, Kintor Pharma announced that its self-developed and potentially first-of-its-kind furitan is an effective treatment for female androgenetic alopecia (AGA).

In recent years, with the increase in the number of people with hair loss, the trend of hair loss is becoming more and more obvious, and the problem of hair loss is gradually becoming the focus of the whole society

Dr.

China Phase II Clinical Trial of Freytan for the Treatment of Female Androgenetic Alopecia

This Phase II clinical trial is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of furatan in the treatment of adult female patients with androgenetic alopecia

*Guidelines for the diagnosis and treatment of androgenetic alopecia in China

About Furitane

Furytan, an androgen receptor antagonist, is a potential first-in-class topical drug for the treatment of androgenetic alopecia and acne

Source: Kintor Pharmaceuticals

The original is abridged